Valuation: Mabvax Therapeutics Holdings Inc

Market Cap 1.11M 975K 920K 839K 1.57M 106M 1.58M 11.01M 4.26M 54.34M 4.17M 4.08M 175M P/E 2016
-0.93x
P/E 2017 -0.25x
Enterprise Value 3.59M 3.15M 2.98M 2.71M 5.08M 344M 5.11M 35.61M 13.77M 176M 13.48M 13.19M 565M EV / Sales 2016
147x
EV / Sales 2017 -
Free-Float
92.02%
Yield 2016 *
-
Yield 2017 -
Change 5-day change 1-year change 3-year change Capi.($)
-3.30%+1.19%+54.62%+104.15% 71.94B
+1.25%-2.63%+35.88%+77.04% 59.35B
+2.12%+5.79%+32.63%+24.27% 27.16B
-3.06%-4.96%-16.43%+350.25% 26.54B
-0.75%-0.14%-1.23%-5.85% 24.93B
+0.40%+1.47%+21.93%-9.96% 20.61B
-1.70%-3.35%+146.86%+325.69% 15.03B
+0.21%+1.21%-6.26%+493.02% 14.2B
+0.36%-0.56%+49.47%+170.76% 14.36B
Average -0.50%-0.12%+35.27%+169.93% 30.46B
Weighted average by Cap. -0.78%-0.24%+35.60%+131.40%

Financials

2016 2017
Net sales 148K 130K 123K 112K 209K 14.18M 211K 1.47M 568K 7.24M 556K 544K 23.27M -
Net income -17.66M -15.51M -14.63M -13.34M -24.97M -1.69B -25.15M -175M -67.71M -864M -66.3M -64.87M -2.78B -19.02M -16.7M -15.75M -14.36M -26.9M -1.82B -27.08M -189M -72.93M -931M -71.41M -69.86M -2.99B
Net Debt 470K 413K 389K 355K 665K 45.04M 669K 4.66M 1.8M 23M 1.76M 1.73M 73.9M 2.48M 2.18M 2.06M 1.87M 3.51M 238M 3.53M 24.6M 9.51M 121M 9.32M 9.11M 390M
Logo Mabvax Therapeutics Holdings Inc
MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform. The Company is focused on the translation into clinical development of products to address the medical needs in the treatment of cancer and pancreatitis. The Company discovered a pipeline of human monoclonal antibody product candidates based on the immune responses generated by patients. The Company's product pipeline includes ImmunoPET Imaging (MVT-2163) and Radioimmunotherapy (MVT-1075). MVT-2163 is an imaging agent for pancreatic cancer. MVT-1075 is a radioimmunotherapy for pancreatic cancer.
Employees
-